{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:03:02Z","timestamp":1790996582622,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.neuroscience.2015.04.027","type":"journal-article","created":{"date-parts":[[2015,4,20]],"date-time":"2015-04-20T06:19:20Z","timestamp":1429510760000},"page":"389-396","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson\u2019s disease"],"prefix":"10.1016","volume":"298","author":[{"given":"C.","family":"Fidalgo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.K.D.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tronci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Stancampiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Chuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0410-4638","authenticated-orcid":false,"given":"E.","family":"Bezard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Carta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.neuroscience.2015.04.027_b0005","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov Disord"},{"issue":"17","key":"10.1016\/j.neuroscience.2015.04.027_b0010","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.1523\/JNEUROSCI.21-17-06853.2001","article-title":"Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson\u2019s disease","volume":"21","author":"Bezard","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.neuroscience.2015.04.027_b0015","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm875","article-title":"Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function","volume":"9","author":"Bezard","year":"2003","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.neuroscience.2015.04.027_b0020","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.neures.2013.10.002","article-title":"Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia","volume":"77","author":"Bezard","year":"2013","journal-title":"Neurosci Res"},{"issue":"8","key":"10.1016\/j.neuroscience.2015.04.027_b0025","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/mds.25366","article-title":"Study of the anti-dyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia","volume":"28","author":"Bezard","year":"2013","journal-title":"Mov Disord"},{"issue":"6","key":"10.1016\/j.neuroscience.2015.04.027_b0030","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1111\/j.1460-9568.2012.08202.x","article-title":"Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats","volume":"36","author":"Bishop","year":"2012","journal-title":"Eur J Neurosci"},{"issue":"3","key":"10.1016\/j.neuroscience.2015.04.027_b0035","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0006-3223(02)01643-8","article-title":"Is there a role for 5-HT1A agonists in the treatment of depression?","volume":"53","author":"Blier","year":"2003","journal-title":"Biol Psychiatry"},{"issue":"5","key":"10.1016\/j.neuroscience.2015.04.027_b0040","first-page":"78","article-title":"Serotonin system implication in l-DOPA-induced dyskinesia: from animal models to clinical investigations","volume":"20","author":"Carta","year":"2014","journal-title":"Front Neurol"},{"key":"10.1016\/j.neuroscience.2015.04.027_b0045","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in Parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"issue":"Suppl 2","key":"10.1016\/j.neuroscience.2015.04.027_b0050","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/j.parkreldis.2008.04.021","article-title":"Involvement of the serotonin system in L-dopa-induced dyskinesias","volume":"14","author":"Carta","year":"2008","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"10.1016\/j.neuroscience.2015.04.027_b0055","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1124\/mol.114.093302","article-title":"Norepinephrine transporter inhibition with desipramine exacerbates L-DOPA-induced dyskinesia: role for synaptic dopamine regulation in denervated nigrostriatal terminals","volume":"86","author":"Chotibut","year":"2014","journal-title":"Mol Pharmacol"},{"issue":"10","key":"10.1016\/j.neuroscience.2015.04.027_b0060","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1212\/01.WNL.0000161841.41885.80","article-title":"Short-term paroxetine treatment does not alter the motor response to levodopa in PD","volume":"64","author":"Chung","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.neuroscience.2015.04.027_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2013.09.017","article-title":"Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats","volume":"77","author":"Conti","year":"2014","journal-title":"Neuropharmacology"},{"issue":"46","key":"10.1016\/j.neuroscience.2015.04.027_b0070","doi-asserted-by":"crossref","first-page":"16709","DOI":"10.1523\/JNEUROSCI.3736-11.2011","article-title":"Perinatal citalopram exposure selectively increases locus ceruleus circuit function in male rats","volume":"31","author":"Darling","year":"2011","journal-title":"J Neurosci"},{"key":"10.1016\/j.neuroscience.2015.04.027_b0075","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1093\/brain\/awh290","article-title":"Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson\u2019s disease: implications for dyskinesias","volume":"127","author":"de la Fuente-Fern\u00e1ndez","year":"2004","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.neuroscience.2015.04.027_b0080","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00002826-200107000-00005","article-title":"SSRIs do not worsen Parkinson\u2019s disease: evidence from an open-label, prospective study","volume":"24","author":"Dell\u2019Agnello","year":"2001","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"10.1016\/j.neuroscience.2015.04.027_b0085","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/mds.21966","article-title":"Comparison of desipramine and citalopram treatments for depression in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled study","volume":"23","author":"Devos","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.neuroscience.2015.04.027_b0090","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1212\/WNL.45.10.1855","article-title":"Levodopa-induced dyskinesias are improved by fluoxetine","volume":"45","author":"Durif","year":"1995","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.neuroscience.2015.04.027_b0095","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/sj.npp.1300686","article-title":"Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain","volume":"30","author":"El Mansari","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/j.neuroscience.2015.04.027_b0100","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/syn.20630","article-title":"The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats","volume":"63","author":"Eskow","year":"2009","journal-title":"Synapse"},{"key":"10.1016\/j.neuroscience.2015.04.027_b0105","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/mds.25133","article-title":"A critique of available scales and presentation of the non-human primate dyskinesia rating scale","volume":"27","author":"Fox","year":"2012","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.neuroscience.2015.04.027_b0110","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.brainres.2006.12.030","article-title":"Abnormal involuntary movements (AIMs) following pulsatile dopaminergic stimulation: severe deterioration and morphological correlates following the loss of locus coeruleus neurons","volume":"1135","author":"Fulceri","year":"2007","journal-title":"Brain Res"},{"issue":"4","key":"10.1016\/j.neuroscience.2015.04.027_b0115","first-page":"9","article-title":"How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs","volume":"57","author":"Goodwin","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.neuroscience.2015.04.027_b0120","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1460-9568.2005.04196.x","article-title":"Levodopa-induced dyskinesia in MPTP-treated macaque is not dependent of the extent and pattern of the nigrostrial lesion","volume":"22","author":"Guigoni","year":"2005","journal-title":"Eur J Neurosci"},{"issue":"3","key":"10.1016\/j.neuroscience.2015.04.027_b0125","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1124\/jpet.102.039743","article-title":"Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates","volume":"303","author":"Hansard","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"19","key":"10.1016\/j.neuroscience.2015.04.027_b0130","doi-asserted-by":"crossref","first-page":"7190","DOI":"10.1523\/JNEUROSCI.1171-11.2011","article-title":"Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time","volume":"31","author":"Huot","year":"2011","journal-title":"J Neurosci"},{"key":"10.1016\/j.neuroscience.2015.04.027_b0135","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.neuropharm.2014.01.012","article-title":"UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances l-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset","volume":"82","author":"Huot","year":"2014","journal-title":"Neuropharmacology"},{"issue":"210","key":"10.1016\/j.neuroscience.2015.04.027_b0140","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.neuroscience.2012.02.024","article-title":"Antidepressants reduce extinction-induced withdrawal and biting behaviors: a model for depressive-like behavior","volume":"17","author":"Huston","year":"2012","journal-title":"Neuroscience"},{"issue":"27","key":"10.1016\/j.neuroscience.2015.04.027_b0145","doi-asserted-by":"crossref","first-page":"9107","DOI":"10.1523\/JNEUROSCI.23-27-09107.2003","article-title":"3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates","volume":"23","author":"Iravani","year":"2003","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.neuroscience.2015.04.027_b0150","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00213-007-0826-8","article-title":"Long-term administration of citalopram reduces basal and stress-induced extracellular noradrenaline levels in rat brain","volume":"194","author":"Kawahara","year":"2007","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.neuroscience.2015.04.027_b0155","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/mds.25859","article-title":"Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson\u2019s disease","volume":"29","author":"Ko","year":"2014","journal-title":"Mov Disord"},{"issue":"223","key":"10.1016\/j.neuroscience.2015.04.027_b0160","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.neuroscience.2012.07.064","article-title":"Distance from source of reward as a marker for extinction-induced \u201cdespair\u201d: modulation by the antidepressants clomipramine and citalopram","volume":"25","author":"Komorowski","year":"2012","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.neuroscience.2015.04.027_b0165","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/00002826-198602000-00005","article-title":"Effects of citalopram, a specific serotonin uptake inhibitor, in tardive dyskinesia and parkinsonism","volume":"9","author":"Korsgaard","year":"1986","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.neuroscience.2015.04.027_b0170","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00213-007-1030-6","article-title":"The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson\u2019s disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram","volume":"197","author":"Kuan","year":"2008","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.neuroscience.2015.04.027_b0175","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1034\/j.1600-0773.2002.900603.x","article-title":"Effects of chronic citalopram treatment on central and peripheral spontaneous open-field behaviours in rats","volume":"90","author":"Kugelberg","year":"2002","journal-title":"Pharmacol Toxicol"},{"issue":"2","key":"10.1016\/j.neuroscience.2015.04.027_b0180","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.neuroscience.2009.08.010","article-title":"Stress sensitive female macaques have decreased fifth Ewing variant (Fev) and serotonin-related gene expression that is not reversed by citalopram","volume":"164","author":"Lima","year":"2009","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.neuroscience.2015.04.027_b0185","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1353-8020(99)00050-4","article-title":"Worsening of Parkinson\u2019s disease by citalopram","volume":"6","author":"Linazasoro","year":"2000","journal-title":"Parkinsonism Relat Disord"},{"issue":"1461","key":"10.1016\/j.neuroscience.2015.04.027_b0190","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.brainres.2012.04.032","article-title":"Buspirone: what is it all about?","volume":"21","author":"Loane","year":"2012","journal-title":"Brain Res"},{"issue":"1","key":"10.1016\/j.neuroscience.2015.04.027_b0195","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson\u2019s disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur J Neurosci"},{"issue":"3","key":"10.1016\/j.neuroscience.2015.04.027_b0200","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/ane.12314","article-title":"Serotonergic antidepressant drugs and L-dopa-induced dyskinesias in Parkinson\u2019s disease","volume":"131","author":"Mazzucchi","year":"2015","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"10.1016\/j.neuroscience.2015.04.027_b0205","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1176\/jnp.16.3.315","article-title":"Citalopram treatment of depression in Parkinson\u2019s disease: the impact on anxiety, disability, and cognition","volume":"16","author":"Menza","year":"2004","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"10","key":"10.1016\/j.neuroscience.2015.04.027_b0210","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1212\/01.wnl.0000336340.89821.b3","article-title":"A controlled trial of antidepressants in patients with Parkinson disease and depression","volume":"72","author":"Menza","year":"2009","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.neuroscience.2015.04.027_b0215","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/WNF.0b013e318210ea3e","article-title":"Citalopram-induced parkinsonian syndrome: case report","volume":"34","author":"Mileti\u0107","year":"2011","journal-title":"Clin Neuropharmacol"},{"issue":"12","key":"10.1016\/j.neuroscience.2015.04.027_b0220","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1093\/brain\/awn235","article-title":"Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia","volume":"131","author":"Mu\u00f1oz","year":"2008","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.neuroscience.2015.04.027_b0225","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.nbd.2010.01.012","article-title":"Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson\u2019s disease","volume":"38","author":"Navailles","year":"2010","journal-title":"Neurobiol Dis"},{"issue":"260","key":"10.1016\/j.neuroscience.2015.04.027_b0230","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.neuroscience.2013.12.029","article-title":"Serotonergic nerve fibers in L-DOPA-derived dopamine release and dyskinesia","volume":"28","author":"Nevalainen","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuroscience.2015.04.027_b0235","series-title":"The rat brain in stereotaxic coordinates","author":"Paxinos","year":"1998"},{"issue":"3","key":"10.1016\/j.neuroscience.2015.04.027_b0240","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1172\/JCI71640","article-title":"Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson\u2019s disease patients","volume":"124","author":"Politis","year":"2014","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.neuroscience.2015.04.027_b0245","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00002826-200201000-00004","article-title":"The SSRI, citalopram, improves bradykinesia in patients with Parkinson\u2019s disease treated with L-dopa","volume":"25","author":"Rampello","year":"2002","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"10.1016\/j.neuroscience.2015.04.027_b0250","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1586\/14737175.7.1.75","article-title":"Regulators of G-protein-coupled receptor-G-protein coupling: antidepressants mechanism of action","volume":"7","author":"Schreiber","year":"2007","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.neuroscience.2015.04.027_b0255","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.expneurol.2014.04.011","article-title":"Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA induced dyskinesia in a rat model of Parkinson\u2019s disease","volume":"257","author":"Shin","year":"2014","journal-title":"Exp Neurol"},{"issue":"1","key":"10.1016\/j.neuroscience.2015.04.027_b0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1461145700001772","article-title":"Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors","volume":"3","author":"Szabo","year":"2000","journal-title":"Int J Neuropsychopharmacol"},{"issue":"3","key":"10.1016\/j.neuroscience.2015.04.027_b0265","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00001756-199902250-00034","article-title":"Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats","volume":"10","author":"Tanaka","year":"1999","journal-title":"Neuroreport"},{"issue":"1","key":"10.1016\/j.neuroscience.2015.04.027_b0270","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.baga.2012.12.002","article-title":"5-HT1 receptor agonists for the treatment of L-DOPA-induced dyskinesia: from animal models to clinical investigation","volume":"3","author":"Tronci","year":"2013","journal-title":"Basal Ganglia"},{"issue":"2","key":"10.1016\/j.neuroscience.2015.04.027_b0275","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.neures.2012.03.004","article-title":"Amphetamine-induced rotation and L-DOPA-induced dyskinesia in the rat 6-OHDA model: a correlation study","volume":"73","author":"Tronci","year":"2012","journal-title":"Neurosci Res"},{"key":"10.1016\/j.neuroscience.2015.04.027_b0280","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.nbd.2013.08.014","article-title":"5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson\u2019s disease model","volume":"60","author":"Tronci","year":"2013","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neuroscience.2015.04.027_b0285","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuroscience.2014.01.042","article-title":"Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson\u2019s disease","volume":"265","author":"Tronci","year":"2014","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/j.neuroscience.2015.04.027_b0290","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000319257","article-title":"Interactions of corticotropin-releasing factor, urocortin and citalopram in a primate model of stress-induced amenorrhea","volume":"92","author":"Weissheimer","year":"2010","journal-title":"Neuroendocrinology"},{"issue":"2","key":"10.1016\/j.neuroscience.2015.04.027_b0295","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.bbr.2007.07.002","article-title":"Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats","volume":"184","author":"Winter","year":"2007","journal-title":"Behav Brain Res"},{"issue":"10","key":"10.1016\/j.neuroscience.2015.04.027_b0300","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/ar.21350","article-title":"Altered expression of tyrosine hydroxylase in the locus coeruleus noradrenergic system in citalopram neonatally exposed rats and monoamine oxidase a knock out mice","volume":"294","author":"Zhang","year":"2011","journal-title":"Anat Rec"}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452215003681?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452215003681?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T13:54:00Z","timestamp":1651758840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452215003681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":60,"alternative-id":["S0306452215003681"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2015.04.027","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}